open access

Vol 9, No 2 (2013)
Case report
Published online: 2013-04-26
Get Citation

Perforation of the small intestine as an early complication of R-CHOP immunochemotherapy in patients with DLBCL — a report of two cases

Marcin Bojo, Ewa Kalinka-Warzocha, Maria Błasińska-Morawiec
Onkol. Prak. Klin 2013;9(2):84-87.

open access

Vol 9, No 2 (2013)
CASE REPORT
Published online: 2013-04-26

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in adult patients. The R-CHOP regimen (rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone) is the gold standard of the treatment for patients with DLBCL. Different adverse events are observed during this treatment, for example: adverse events related to the infusion (cytokine release syndrome, tumor lysis syndrome), hematologic events, cardiovascular events, infections. Perforations of the stomach and small intestine are rare but life-threatening complications of the R-CHOP immunochemotherapy. We present two patients with DLBCL, who were treated with R-CHOP regimen. Both had perforation of the small intestine shortly after first cycle. One of them underwent partial resection of the small intestine, another had enterorhaphy. Intraoperatively no neoplastic infiltration of gastrointestinal tract was noted. After recovery the patients continued R-CHOP immunochemotherapy achieving complete remission.

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in adult patients. The R-CHOP regimen (rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone) is the gold standard of the treatment for patients with DLBCL. Different adverse events are observed during this treatment, for example: adverse events related to the infusion (cytokine release syndrome, tumor lysis syndrome), hematologic events, cardiovascular events, infections. Perforations of the stomach and small intestine are rare but life-threatening complications of the R-CHOP immunochemotherapy. We present two patients with DLBCL, who were treated with R-CHOP regimen. Both had perforation of the small intestine shortly after first cycle. One of them underwent partial resection of the small intestine, another had enterorhaphy. Intraoperatively no neoplastic infiltration of gastrointestinal tract was noted. After recovery the patients continued R-CHOP immunochemotherapy achieving complete remission.
Get Citation

Keywords

DLBCL-lymphoma, R-CHOP immunochemotherapy, perforation of the small intestine

About this article
Title

Perforation of the small intestine as an early complication of R-CHOP immunochemotherapy in patients with DLBCL — a report of two cases

Journal

Oncology in Clinical Practice

Issue

Vol 9, No 2 (2013)

Article type

Case report

Pages

84-87

Published online

2013-04-26

Bibliographic record

Onkol. Prak. Klin 2013;9(2):84-87.

Keywords

DLBCL-lymphoma
R-CHOP immunochemotherapy
perforation of the small intestine

Authors

Marcin Bojo
Ewa Kalinka-Warzocha
Maria Błasińska-Morawiec

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl